Replies to post #67383 on Biotech Values

[DewDiligence]

Today was a busy news day for ABT. In addition to announcing a $5B share buyback, ABT released data at the TCT conference on Xience and the bioabsorbable stent in development.

In head-to-head studies, Xience bested BSX’s Taxus on both MACE and TLR at two years:
http://biz.yahoo.com/prnews/081013/aqm519.html

ABT’s bioabsorbable stent demonstrated decent results and confirmed bioabsorption in a pilot single-arm study with 30 patients:
http://biz.yahoo.com/prnews/081013/aqm521.html

I think it’s fair to say that ABT is now generally perceived to be the technology leader in the field of drug-eluting stents.